MedTrace Logo

A Positron Emission Tomography Occupancy Study Using Ligand [11C]AS2471907 and Following Oral Dosing of ASP3662

NCT02194491 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2016-06-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate a novel PET tracer (\[11C\]AS2471907), and to use \[11C\]AS2471907 to assess the level and time-course of enzyme occupancy in the human brain prior to and following single oral dose administration of ASP3662.

Conditions

  • Pharmacokinetics of ASP3662
  • Displacement of Radiotracer
  • Healthy Volunteers

Interventions

OTHER

[11C]AS2471907

intravenous radiotracer

RADIATION

Positron Emission Tomography (PET)

Imaging scanning procedure

DRUG

ASP3662

oral

Sponsors & Collaborators

  • Yale University

    collaborator OTHER

  • Astellas Pharma Global Development, Inc.

    lead INDUSTRY

Principal Investigators

  • Senior Medical Director · Astellas Pharma Global Development, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2016-05-31
Completion
2016-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02194491 on ClinicalTrials.gov